Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Why Krypton Street is Highlighting (NASDAQ: RNAZ)
This Morning—Wednesday, June 3, 2026…
Get Our Real-Time Updates Sent Directly To Your Phone. Up To 10X Faster Than Email.
Pull Up RNAZ While It’s Still Early… June 3, 2026
Pull Up (NASDAQ: RNAZ) Early Because There’s Under 900K Shares Listed in its Float Dear Reader, A clinical-stage company just did something that rarely happens all at once: it entered Phase 2a with its lead candidate, locked in up to $20M in flexible financing to extend its runway into late 2027/early 2028, and secured a worldwide royalty-free license to a next-generation oncolytic platform — all within a span of roughly 90 days. That company is TransCode Therapeutics, Inc. (NASDAQ: RNAZ), and the back-to-back potential catalysts deserve a closer look. And that’s exactly why (RNAZ) is topping our watchlist this morning—Wednesday, June 3, 2026. But keep in mind, RNAZ has less than 900K shares listed as available in its public float. When companies have small floats like this, the potential exists for big moves if demand begins to shift. From a technical standpoint, Barchart data currently shows RNAZ's near-term RSI levels in the 20–30 range — a zone commonly interpreted by technical analysts as “oversold territory.” 
Over the last week, RNAZ has made an approximate 14% move, from around $5.01 on May 27 to $5.75 on June 1. About TransCode Therapeutics
TransCode Therapeutics is a Boston-based, clinical-stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. Its lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b (miR-10b) — a unique, well-documented biomarker of metastasis found across multiple cancer types. TTX-MC138 is designed to silence this microRNA, disrupting its role in promoting cancer cell spread and survival. Beyond TTX-MC138, TransCode has assembled a growing portfolio of first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The company's immuno-oncology approach includes RIG-I immunotherapeutic candidates and, most recently, a trio of oncolytic adeno-vi-rus platforms. The market context: the global oncology market is projected to grow from around $279B in 2026 to over $732B within the next 10 years — a near-tripling driven by the demand for targeted, precision oncology solutions. 
RNA-based therapeutics and immuno-oncology are two of the fastest-growing verticals within that expansion, and both sit at the core of what RNAZ is building. Phase 2a Is Live — And the Target Is Minimal Residual Disease
On May 27, 2026, TransCode announced the initiation of its Phase 2a clinical trial evaluating TTX-MC138 in patients with ctDNA-positive colorectal cancer following curative-intent therapy. The trial is conducted in collaboration with Quantum Leap Healthcare Collaborative (QLHC) through its PRE-I-SPY clinical trial platform — a leading platform for innovative oncology trials and the program's first expansion into colorectal cancer. The trial is expected to enroll up to 45 patients and is led by Principal Investigator Dr. Paula Pohlmann of MD Anderson Cancer Center. The study has received both FDA IND submission acknowledgment and full Institutional Review Board (IRB) approval, enabling site activation and the commencement of patient enrollment. The focus is on minimal residual disease (MRD) — patients who've completed curative therapy and show no radiographic evidence of disease, but still test positive for circulating tumor DNA, meaning microscopic cancer cells may remain. This is one of the most underserved clinical windows in all of oncology, where early intervention could meaningfully alter long-term outcomes. TTX-MC138 is being positioned precisely here — before overt relapse, while the target cell burden is lowest and the potential for durable response is theoretically highest. A Pipeline Expanding in Multiple Directions
In March 2026, TransCode secured an exclusive, worldwide, royalty-free license from Unleash Immuno Oncolytics, gaining rights to three adeno-vi-rus-based oncolytic candidates — UIO-524, UIO-525, and UIO-526. The lead candidate, UIO-524, targets muscle-invasive bladder cancer (MIBC), a high-unmet-need indication characterized by a highly immunosuppressive tumor microenvironment and limited durable treatment options. The deal was structured entirely in equity — no cash deployed — preserving the company's operating capital. In April 2026, the company appointed Dr. Anna Moore, PhD — a TransCode co-founder and globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics — as Chair of its Scientific Advisory Board. Dr. Moore brings a 26-year research career at Massachusetts General Hospital (MGH) and Harvard Medical School to that role. A concurrent research agreement with Michigan State University is structured to support preclinical and translational studies, including evaluation of TTX-MC138 in combination with Seviprotimut-L and standard-of-care therapies. Runway Extended, Balance Sheet FortifiedOn April 7, 2026, TransCode entered into agreements for up to $20M in flexible financing. Management has stated this arrangement extends the company’s runway into late 2027/early 2028, providing additional flexibility as TransCode advances its Phase 2a clinical program for TTX-MC138 and continues expanding its broader oncology pipeline. For a clinical-stage biotechnology company, access to capital can be an important component of execution, allowing the company to focus on key clinical milestones, ongoing research initiatives, and the continued advancement of its therapeutic candidates. 7 Reasons RNAZ is Topping Our Watchlist This Morning—Wednesday, June 3, 2026…1. Small Float: With less than 900K shares listed as available to the public, RNAZ’s small float could witness the potential for big moves if demand begins to shift. 2. RSI Setup: With near-term RSI levels shown in the 20–30 range, RNAZ appears to be sitting in a technical zone often viewed as oversold. 3. Phase 2a Live: With its Phase 2a clinical trial now initiated, RNAZ has a current clinical milestone that market watchers can track in real time. 4. Extended Runway: After securing up to $20M in flexible financing, RNAZ says its runway now extends into late 2027/early 2028. 5. Growing Market: RNAZ is operating within the global oncology market, which is projected to expand from approximately $279B in 2026 to more than $732B over the next decade. 6. Pipeline Expansion: Through a worldwide royalty-free license, RNAZ added three oncolytic adeno-vi-rus candidates to its broader oncology pipeline. 7. Scientific Leadership: With Dr. Anna Moore appointed Chair of the Scientific Advisory Board, RNAZ added leadership tied to MGH, Harvard Medical School, and RNA-targeted cancer research. Pull Up RNAZ While It’s Still Early…
From where we sit at Krypton Street, the convergence of events around RNAZ over the past 90 days is hard to ignore. A Phase 2a trial now actively enrolling at MD Anderson, a balance sheet extended into late 2027/early 2028, a pipeline that now spans RNA silencing and oncolytic immunotherapy, and scientific leadership with elite academic credentials — all while technical indicators suggest the name may be trending in compressed territory. Whether RNAZ becomes a major clinical story will ultimately depend on data, but the operational architecture being assembled here is worth watching closely. We'll be watching RNAZ as Phase 2a enrollment progresses and the company moves toward its first clinical readouts. Pull up RNAZ while it’s still early.
Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter |
